Single agent anti-PD-1 versus combined BRAF and MEK inhibitors upfront in metastatic or unresectable BRAF V600 mutated melanoma - A EUMelaReg real world evidence study
to differentiate true progression from pseudoprogression.Further research should focus on identifying biomarkers to guide therapy for patients with oligoprogressive disease.
Authors
- Nethanel Asher (ORCID: https://orcid.org/0000-0002-4094-8045)
- H. Gogas
- M. Weichenthal
- D. Schadendorf
- P.A. Ascierto
- J.B.A.G. Haanen
- Enrique Espinosa (ORCID: https://orcid.org/0000-0001-6562-7902)
- P. Rutkowski
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- I. Gavrilova
- J. Mangana
- Lidija Kandolf
Institutions
- Military Medical Academy (RS)
- National and Kapodistrian University of Athens (GR)
- Rabin Medical Center (IL)
- Hospital Universitario La Paz (ES)
- Odense University Hospital (DK)
- The Netherlands Cancer Institute (NL)
- Christian-Albrechts-Universität zu Kiel (DE)
- University Hospital of Zurich (CH)
- University Hospital Schleswig-Holstein (DE)
- National Heart Hospital (BG)
- Essen University Hospital (DE)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- University of Lübeck (DE)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100526
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81